CANCER RISK WITH TOPICAL PIMECROLIMUS AND TACROLIMUS FOR ATOPIC DERMATITIS: SYSTEMATIC REVIEW AND BAYESIAN META-ANALYSIS

Introduction Atopic dermatitis (AD) affects millions worldwide and is effectively managed by topical treatments, including the topical calcineurin inhibitors (TCIs), pimecrolimus and tacrolimus. In 2005 and 2011, the FDA released reviews associating TCIs with theoretical cancer risk, albeit with uncertainty. We systematically reviewed the cancer risk in patients with AD exposed to TCIs. Methods The AAAAI/ACAAI Joint Task Force on Practice …